New Analysis of Rekovelle® Data Further Supports Use of AMH to Personalise Fertility Treatment
Ferring Pharmaceuticals announced today a new analysis* of data from the Phase 3 ESTHER-1 trial1 showing that natural variations in anti-Müllerian hormone (AMH) levels during and between a woman’s menstrual cycle have no clinically relevant impact on ovarian response (the number of eggs produced) when using AMH to dose Rekovelle ® (follitropin delta) for ovarian stimulation (OS).2 The data were presented today at the 34th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Barcelona, Spain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180701005093/en/
AMH Infographic (Photo: Business Wire)
According to the new analysis, for 95% of women treated with Rekovelle, variations in ovarian response were limited to a difference of plus or minus one egg.2 This reinforces that AMH measured on any day of a woman’s menstrual cycle can be used to individualise the dose of Rekovelle. AMH is measured with a companion diagnostic, the Elecsys® AMH Plus immunoassay from F. Hoffmann-La Roche Ltd (Roche).
“We are excited to share the results of this new Rekovelle analysis which add to existing evidence showing AMH is a robust predictor of ovarian response to fertility treatment,” said Professor Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. “I believe these data will further strengthen the growing confidence of doctors in the use of AMH to personalise dosing of fertility treatment for their patients.”
Ovarian response to stimulation varies considerably from woman to woman3 and unexpected extreme responses have implications on efficacy and safety.4,5 Aiming to avoid extremes in ovarian response, the validated Rekovelle dosing algorithm uses AMH and body weight to determine a personalised dose for patients, from the start of treatment.
This analysis of data from the Phase 3 ESTHER-1 trial adds to consistent efficacy results seen with Rekovelle in clinical trials to date. The ESTHER-1 trial showed that women undergoing their first treatment cycle receiving individualised treatment with Rekovelle, compared to conventional dosing regimen with follitropin alfa,Ɨǂ had similar ongoing pregnancy and embryo implantation rates.1
The ESTHER-1 trial also showed that more women receiving individualised treatment with Rekovelle achieved the target response of 8-14 eggs compared to conventional dosing regimen with follitropin alfa.1ǂ§ Evidence shows that beyond 15 eggs there is no additional benefit, in terms of live birth rate, in the number of eggs produced through OS in a fresh cycle.6,7
About Rekovelle (follitropin delta)
Rekovelle is a human recombinant follicle stimulating hormone (rFSH) with an approved dosing algorithm designed for predictable ovarian response.8 It is the first rFSH derived from a human cell line (PER.C6® cell line). Rekovelle is structurally and biochemically distinct from other existing rFSH gonadotrophins.8,9 Rekovelle is approved for use in ovarian stimulation (OS) for induction of the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI).8 The individualised dosing of Rekovelle is determined using an approved algorithm, based on a woman’s anti-Müllerian hormone (AMH) level and body weight.1,8,10 AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response.11 AMH will be measured with a companion diagnostic, the Elecsys® AMH Plus immunoassay from F. Hoffmann-La Roche Ltd (Roche).12,13
As of 15 June 2018, Rekovelle was approved in 37 countries and available in 17 countries worldwide.
About the ESTHER trials
The ESTHER trials (Evidence-based Stimulation Trial with Human recombinant FSH in Europe and Rest of World) were randomised, assessor-blind, controlled, multicentre Phase 3 trials involving patients in 11 countries and over 2,000 cycles of OS.1,14
ESTHER-1 was a trial of 1,326 patients in 11 countries undergoing their first ART cycle. Patients were randomised 1:1 to receive treatment with individualised Rekovelle, a fixed daily dose based on serum AMH levels** and body weight, or conventional follitropin alfa dosing.1ǂ The co-primary endpoints of ongoing pregnancy rates and ongoing implantation rates were met, demonstrating comparable efficacy of Rekovelle to conventional treatment.1 Rekovelle’s individualised dosing regimen aims to obtain an ovarian response associated with a favourable safety/efficacy profile, i.e. aims to achieve an adequate number of eggs and reduce interventions to prevent ovarian hyperstimulation syndrome.8
ESTHER-2 evaluated the immunogenicity of Rekovelle in a subset of ESTHER-1 patients undergoing repeated cycles of OS for ART. Data demonstrated no increased immunogenicity risk with Rekovelle after exposure in repeated cycles.8,14
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
About the Elecsys
AMH Plus immunoassay from
The Elecsys® AMH Plus immunoassay from Roche has been shown to provide a precise, reliable and robust measurement of AMH levels.12,13,15,16,17,18 This fully automated Elecsys® AMH Plus immunoassay, run on the cobas ® e and Elecsys® immunoassay analysers, determines AMH levels in 18 minutes, making it appropriate for routine clinical use. The Elecsys® AMH Plus immunoassay is intended to be used for assessment of ovarian reserve, prediction of response to OS and establishment of the individual daily dose of Ferring follitropin delta in combination with body weight in OS for the development of multiple follicles in women undergoing an assisted reproductive technology programme.8,12,15,17,18
1 Nyboe Andersen A, Nelson SM, Fauser BC, et al. Individualised versus conventional ovarian stimulation for an in vitro fertilization: a multicenter, randomized, controlled assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017 02 [cited 2018 Jun 14];107(2):387-396.
2 Nelson SM, Larsson P, Mannaerts B, et al. AMH variability and its implications for the number of oocytes retrieved following individualized dosing with follitropin delta [abstract]: 34th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2018; Barcelona, Spain. Abstract no P-651.
3 Fauser BC, Diedrich K, Devroey P. Evian Annual Reproduction Workshop Group 2007. Hum Reprod Update; 2008 02 [cited 2018 Jun 14];14:1–14.
4 La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014 01 [cited 2018 Jun 14;20:124–40.
5 Steward RG, Lan L, Shah AA, et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril. 2014 04 [cited 2018 Jun 14];101:967–973.
6 Drakopoulos P, Blockeel C, Stoop D, et al. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016 02 [cited 2018 Jun 14];31(2):370-376.
7 Ji J, Liu Y, Hong Tong X, et al. The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China. Hum Reprod. 2013 10 [cited 2018 Jun 14];28(10):2728-2734.
8 Rekovelle® Summmary of Product Characteristics. Date of publication 2016 12 [cited 2018 Jun 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003994/WC500220238.pdf.
9 Olsson H, Sandström R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. Journal of Clinical Pharmacology. 2014 11 [cited 2018 Jun 14];54(11):1299–307.
10 Arce JC, Nyboe Andersen A, Fernandez Sanchez M, et al. Ovarian response to recombinant human follicle stimulating hormone: a randomized, anti-Müllerian hormone–stratified, dose–response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertility and Sterility. 2014 12 [cited 2018 Jun 14];102(6):1633–1640.
11 La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010 03 [cited 2018 Jun 14];16(2):113-130.
12 Deeks ED. Elecsys® AMH assay: a review in anti-Müllerian hormone quantification and assessment of ovarian reserve. Molecular Diagnosis & Therapy. 2015 07 [cited 2018 Jun 14];19: 245-249.
13 Roche Diagnostics. Elecsys® AMH (anti-Müllerian hormone): Method sheet. (2015). Date of publication 2014 [cited 2018 Jun 14]. Available from: http://www.cobas.com/content/dam/cobas_com/pdf/product/Elecsys%20AMH/Elecsys%20AMH%20FactSheet.pdf.
14 Buur Rasmussen A, Mannaerts B, Klein BM, et al. Low immunogenicity potential of follitropin delta, a recombinant FSH preparation produced from a human cell line: Results from phase 3 trials (ESTHER-1 and ESTHER-2). Human Reproduction. 2016 07 [cited 2018 Jun 14];31:385.
15 Gassner D. & Jung R. First fully automated immunoassay for anti-Müllerian hormone. Clinical Chemistry and Laboratory Medicine. 2014 08 [cited 2018 Jun 14];52(8):1143-1152.
16 Anderson RA, Anckaert E, Bosch E, et al. Prospective study into the value of the automated Elecsys® Anti-Müllerian Hormone assay for the assessment of the ovarian growing follicle pool. Fertility and Sterility. 2015 04 [cited 2018 Jun 14];103(4):1074–1080.e4.
17 Nelson SM, Pastuszek E, Kloss G, et al. Two new automated, compared with two enzyme-linked immunosorbent anti-Müllerian hormone assays. Fertility and Sterility. 2015 07 [cited 2018 Jun 14];104(4):1016-1021.e6.
18 Hyldgaard J, Bor P, Ingerslev HJ, et al. Comparison of two different methods for measuring anti-Müllerian hormone in a clinical series. Reproductive Biology and Endocrinology. 2015 09 [cited 2018 Jun 14];13(1):107.
* A sub-analysis of the ESTHER-1 study population including 1,326 women (aged 18-40 years). Serum AMH was measured at a random day at screening and at cycle day 2-3 prior to stimulation using the Elecsys® AMH Plus immunoassay (Roche). Limitations: A centralised AMH measuring laboratory was used which may give rise to reduced AMH variability. AMH measurements were compared with samples taken within 3 months prior to ovarian stimulation, longer time intervals may have shown different variability due to the age-related decline in AMH.
Ɨ GONAL-f ® , registered trademark of Merck KGaA, Darmstadt, Germany.
ǂ Conventional dosing of follitropin alfa is 150 IU/d for 5 days, with potential subsequent dose adjustments at a maximum of 450 IU/d.1
§ ESTHER-1 was neither designed nor powered to assess results based on secondary endpoints. Predefined secondary endpoints are used as a measurement to yield supportive evidence to evaluate additional effects relevant to informing the Rekovelle individualised dosing regimen. No confirmatory conclusions can be derived.
** AMH is measured by a companion diagnostic, the Elecsys® AMH Plus immunoassay from F. Hoffmann-La Roche Ltd (Roche).
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
In Preparation for the 2019 Proxy Season, CGLytics Expands Global Coverage and Appoints New Head of Research20.2.2019 22:10:00 | Tiedote
In recent years, increased shareholder activism and an overall heightened awareness of companies’ governance practices, has led to the need for greater transparency of exposure to governance and reputational risks. CGLytics, a leading corporate governance analytics provider, is continuing to drive transparency of good governance practices for better informed decision-making, by expanding its global coverage. Part of the expanded global coverage for its powerful, cloud-based governance platform includes an increase of company data from 3,300 to 5,500 listed companies across North America, Europe and Australia. This increase provides companies and investors with the deepest global governance data set in the market to date. For Investors, this increase in coverage will permit a substantially broader reach when analysing the potential governance risk in their portfolios, allowing for better engagement, decision-making and stewardship. Moreover, Issuers will gain a more in-depth capacity to
Payments Canada Selects SIA As the Application Provider for Canada’s New High-Value Payments System, Lynx20.2.2019 18:30:00 | Tiedote
Payments Canada announced today the selection of SIA as the application provider for the country’s new high-value payments system, Lynx. This payments Modernization milestone is the outcome of an extensive procurement process with participation from key industry partners, including Canadian financial institutions. In April 2017, Payments Canada announced a list of suppliers invited to participate in a competitive procurement process for Lynx. This process has ended, and Payments Canada has selected SIA as the Lynx application provider, subject to negotiation of the final agreement and final regulatory approval. SIA will work closely with Payments Canada and key industry stakeholders on the next version of their Real-Time Gross Settlement (RTGS) application solution to deliver on the needs identified during consultations for the future of payments in Canada, in compliance with strict Canadian and international risk standards. SIA is well known in the global landscape as a leader in paym
Arch Capital Group Ltd. Names Janice Englesbe Senior Vice President, Chief Risk Officer20.2.2019 18:10:00 | Tiedote
Arch Capital Group Ltd. (“Arch”) today announced that Janice Englesbe will join the Company as Senior Vice President, Chief Risk Officer (CRO) effective February 25, 2019. Ms. Englesbe will be based in Arch’s Bermuda office and report to François Morin, the Company’s Executive Vice President and Chief Financial Officer. As CRO, Ms. Englesbe will have overall responsibility for the Company’s risk management function. Additionally, she will help formulate and implement business strategies and provide comprehensive counsel to the executive leaders and board members. “Janice brings a wealth of experience and demonstrated ability to implement practical results,” Mr. Morin said. “I’m looking forward to the unique perspective and leadership she will bring to Arch.” Ms. Englesbe has over 25 years of risk and finance experience, including Group Deputy Chief Risk Officer of General Re, and has been named one of Intelligent Insurer’s 100 Influential Women in Re/insurance. She holds a bachelor’s d
Ingram Micro and MassChallenge Name Comet Competition Top B2B Startups20.2.2019 18:00:00 | Tiedote
Ingram Micro Inc., in partnership with MassChallenge, today announced the top 12 finalists from its Tel Aviv, Austin, and Boston Comet Competition s. The finalists for this year’s inaugural competition are Verifyoo, Perimeter 81, ITsMine, EyeControl, ClearBlade, re:3D, Sempulse, The Mentor Method, Pixm Inc., addapptation, OnRout, and BOXOLOGIC.COM. Established in 2018, the Comet Competition is the only startup challenge dedicated to discovering talented B2B independent software vendors (ISVs) and accelerating their trajectory to channel market success. As Comet Competition finalists, these startups will receive go-to-market funding, unparalleled access to top corporate partners, and tailored curriculum to accelerate their success – all for zero equity. “In order to continue to be a leader in the digital economy, we need to actively search for the world’s best technology startups and catapult their trajectory to profitability and scale,” says Nimesh Davé, executive vice president, Ingra
KCI Launches ABTHERA™ Therapy in Japan20.2.2019 17:30:00 | Tiedote
KCI, an Acelity Company, today announced the launch of ABTHERA™ Open Abdomen Negative Pressure Therapy in Japan, expanding access to the Company’s surgical portfolio in the country. ABTHERA™ Therapy is a temporary abdominal closure system that allows surgeons to take control in managing challenging abdominal wall openings where primary closure is not possible and/or repeat abdominal entries are necessary. “When dealing with patients managed with damage control for severe abdominal hemorrhage, abdominal compartment syndrome or severe peritonitis, using ABTHERA™ Therapy has been shown to be associated with proven patient outcomes,” said Dr. Demetrios Demetriades, Professor of Surgery, Keck USC School of Medicine and the Director of the USC Division of Trauma, Emergency Surgery and Surgical Intensive Care Unit. “With the introduction of ABTHERA™ Therapy in Japan, clinicians now have a clinically demonstrated solution for a previously unmet, significant need, that manages the open abdomen
ResMed and Fisher & Paykel Healthcare Announce Settlement of Global Patent Infringement Litigation20.2.2019 17:00:00 | Tiedote
ResMed (NYSE: RMD, ASX: RMD), and Fisher & Paykel Healthcare (NZX: FPH, ASX: FPH) today announced an agreement to settle all outstanding patent infringement disputes between the companies in all venues around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190220005556/en/ The settlement involves no payment or admission of liability by either side. Under the agreement, all ongoing infringement proceedings against named products will be dismissed, and each party will bear its own attorney fees and costs incurred in the global proceedings. All other terms remain confidential. As a result of the settlement, there will be no further infringement proceedings against ResMed products, including AirSense flow generators, AirFit P10, Swift LT and Swift FX masks, and ClimateLine heated tubes; or against Fisher & Paykel Healthcare products including Simplus, Eson and Eson 2. “I am pleased we were able to resolve these dispute
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme